REN and neoplasm: Prior to this trial, preclinical data had demonstrated that angiotensin I receptor inhibitors, which block the renin-angiotensin system, could potentially impede tumor growth and metastasis and ameliorate the effectiveness of systemic therapy by increasing drug delivery to the tumor tissue [67].